Table 1.
Demographics and clinical characteristics of patients.
| Measure | Apo-E status | p value | |
|---|---|---|---|
| Negative | Positive | ||
| N = 71 | N = 150 | ||
| Age (years) | 76.45 ± 9.09 | 73.88 ± 7.75 | 0.019 |
| Gender | |||
| Male | 42 | 86 | 0.066 |
| Female | 29 | 64 | |
| Education (years) | 15.76 ± 2.91 | 15.23 ± 2.92 | 0.183 |
| CDR | 4.51 ± 1.59 | 4.47 ± 1.75 | 0.501 |
| ADAS | 30.48 ± 8.24 | 29.61 ± 8.10 | 0.381 |
|
| |||
| CSF proteins | |||
| Aβ-42 | 854.81 ± 412.66 | 586.47 ± 218.54 | <0.001 |
| TAU | 359.80 ± 163.94 | 375.09 ± 135.07 | 0.215 |
| P-TAU | 35.09 ± 17.87 | 37.82 ± 14.76 | 0.067 |
|
| |||
| Lipoproteins and metabolites∗ | |||
| Phenylalanine | 0.069 ± 0.011 | 0.067 ± 0.010 | 0.049 |
∗Only lipoproteins and metabolites with significant or marginally significant differences mentioned in the table. CDR: clinical dementia rating, ADAS: Alzheimer's disease assessment scale, CSF: cerebrospinal fluid.